Banking

After Disappointing Phase 2 Data, Merck Drops Eye Disease Related Pact With NGM Biopharm

[ad_1] <img class="img-responsive" src="https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2022/12/21/ngm_logo_light__58a0e6464f7ef4d049702f4c4705e5b5.png"><ul>
<li>Merck Co Inc&nbsp;(NYSE:<a class="ticker" href="https://markets.businessinsider.com/stocks/mrk-stock">MRK</a>) has&nbsp;notified&nbsp;NGM Biopharmaceuticals…

[ad_2]

Share this news on your Fb,Twitter and Whatsapp

File source

Times News Network:Latest News Headlines
Times News Network||Health||

Tags
Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close